Biosimilar Antibodies

Rosnilimab is a humanized IgG1 kappa monoclonal antibody specifically designed to target and bind to the programmed cell death protein 1 (PD-1). This interaction inhibits PD-1 signaling, which can enhance the immune system's ability to fight cancer. Rosnilimab is primarily used in research focused on the modulation of immune checkpoints in oncology.

GEN-1044 is a bispecific antibody targeting CD3 and the oncofetal antigen 5T4. This antibody exhibits dual functionality by engaging both the immune system's T cells and the tumor-associated antigen 5T4, thereby facilitating immunomodulatory and antineoplastic activities. This specificity makes GEN-1044 a valuable tool for research in cancer immunotherapy, particularly in studies focused on the mechanisms of T-cell mediated tumor rejection.

Bersanlimab (BI-505) is a fully human monoclonal antibody specifically designed to target and bind to intercellular adhesion molecule-1 (ICAM-1, also known as CD54). This antibody exhibits potent anticancer properties by interfering with ICAM-1 mediated cell adhesion, a process crucial for tumor progression and metastasis. Bersanlimab is utilized extensively in research focused on the development of therapeutic strategies for various cancers.

Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody designed to target and bind to lymphocyte-activation gene 3 (LAG-3). This interaction effectively inhibits the binding of LAG-3 to major histocompatibility complex class II (MHC-II) molecules, which is critical in modulating immune response. Ieramilimab is utilized extensively in research focused on immune checkpoint regulation and potential therapeutic interventions for various immunological disorders.

Rilvegostomig is a human IgG1 κ monoclonal antibody targeting PDCD1 and TIGIT. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

GSK-933776 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Amyloid Beta (Aβ). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.34 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. GSK-933776 is relevant for research into Alzheimer's disease and other amyloid-related disorders, providing a valuable tool for the investigation of amyloid beta dynamics and pathology.

The Anti-vWF Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target von Willebrand Factor (vWF). This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145.62 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control, ensuring accurate and reliable results in research applications.

Laventatug is a humanized monoclonal antibody that specifically targets the human SLC39A6 protein. By binding to SLC39A6, Laventatug disrupts the intracellular transport of zinc ions, a process integral to tumor cell viability and proliferation. This interference with zinc ion homeostasis confers Laventatug with potent antitumor properties, making it an invaluable tool for cancer research, particularly in studies exploring the molecular mechanisms of tumor growth and progression.

Ibentatug is a human IgG1 κ monoclonal antibody targeting CSP1. For experimental rigor and control, it is recommended to use Human IgG1 kappa Isotype Control.

Ichorcumab (JNJ-375) is a fully human monoclonal antibody of the IgG4 subclass, specifically designed to target thrombin. This antibody selectively binds to exosite 1 on thrombin, effectively inhibiting substrate binding while preserving the enzyme's catalytic activity. For experimental controls, the recommended isotype control is Human IgG4 (S228P) kappa.

Gemtuzumab ozogamicin is a monoclonal IgG4-κ antibody specifically targeting the CD33 antigen, predominantly expressed on leukemic myeloblasts in acute myeloid leukemia (AML). This antibody serves as a foundational component for the synthesis of the antibody-drug conjugate (ADC), Gemtuzumab ozogamicin. This conjugate is composed of Gemtuzumab linked to a cytotoxic derivative of Calicheamicin, a potent antibiotic known for its antitumor activity. Gemtuzumab ozogamicin is primarily utilized in research focused on the therapeutic targeting and treatment modalities of acute myeloid leukemia.

Bavituximab is a recombinant monoclonal antibody that targets phosphatidylserine (PS), a key component of the tumor microenvironment. This antibody functions by suppressing tumor growth through dual mechanisms: direct targeting of tumor vasculature and reactivation of antitumor immune responses. In combination with chemotherapeutic agents Paclitaxel and Carboplatin, Bavituximab has demonstrated enhanced inhibitory effects on non-small-cell lung cancer, suggesting its potential utility in oncology research and therapeutic applications.

The Anti-PVRIG Antibody (COM701) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the PVRIG protein. This antibody has a predicted molecular weight of 145.48 kDa. It is of the human IgG4 kappa isotype, and suitable isotype controls are available for experimental validation. This product is ideal for use in research focused on the role of PVRIG in immune modulation and cancer immunotherapy.

Indatuximab is a chimeric antibody of the VHH-Fc (huIgG1) type, expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target Syndecan-1/CD138. This antibody has a predicted molecular weight of 146.1 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended as the isotype control for Indatuximab.

Eglatoprutug is a humanized IgG1-kappa monoclonal antibody that targets the c-Kit receptor. This antibody has been engineered for high specificity and affinity in binding to the c-Kit, which is commonly expressed in various cell types and is involved in numerous cellular processes, including signal transduction and cell proliferation. Eglatoprutug's precise targeting makes it a valuable tool for research focused on c-Kit related pathways and diseases.

Solitomab (AMG 110) is a bispecific antibody designed to target both CD3, a T-cell co-receptor, and Epithelial Cell Adhesion Molecule (EpCAM), which is frequently overexpressed in various carcinomas. This dual targeting mechanism facilitates the redirection of T cells to EpCAM-expressing tumor cells, promoting T-cell mediated cytotoxicity. Solitomab is primarily utilized in research focused on primary uterine and ovarian carcinosarcoma, providing a valuable tool for investigating the therapeutic potential of bispecific antibodies in cancer immunotherapy.

The Anti-AXL / UFO (ORY012) is a polyclonal antibody specifically designed to target the receptor tyrosine kinase AXL, also known as UFO. This antibody is highly relevant for studies focusing on the pathophysiology and therapeutic targeting of cancers such as glioblastoma multiforme (GBM) and pancreatic cancer. Its specificity for the AXL/UFO receptor makes it an invaluable tool for researchers investigating the role of this kinase in cancer progression and response to therapies.

Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody designed to inhibit Wnt pathway signaling. This inhibition is achieved through its specific binding to Frizzled receptors FZD1, FZD2, FZD5, FZD7, and FZD8. The antibody's mechanism of action includes direct effects on tumor cells, including cancer stem cells (CSCs), as well as modulatory effects on the tumor stroma. Vantictumab is primarily researched for its potential therapeutic applications in treating conditions such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.

Amdokitug is a human IgG1 λ monoclonal antibody targeting MUSK. For control experiments, it is recommended to use Human IgG1 Lambda2 as an isotype control.

Eptinezumab is a humanized monoclonal antibody designed to selectively bind to calcitonin gene-related peptide (CGRP), effectively inhibiting its interaction with its receptor. This blockade of CGRP, a neuropeptide involved in migraine pathogenesis, makes eptinezumab an effective preventive treatment for migraine in adults. Its targeted mechanism of action positions it as a critical tool for research in neurology and headache disorders.

Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody engineered to concurrently target and inhibit the human epidermal growth factor receptor 2 (HER2) and the programmed death receptor-1 (PD-1). By binding to these receptors, Fidasimtamab disrupts downstream signaling pathways, thereby exerting potential immunosuppressive and antitumor effects. This antibody facilitates the linkage of PD-1 expressing T cells to HER2 expressing tumor cells, enhancing immune-mediated tumor cell killing. Fidasimtamab is under investigation for its therapeutic efficacy in various oncological applications.

Vonsetamig is a bispecific antibody comprising humanized immunoglobulin G4-kappa that targets both TNFRSF17 and CD3E. This therapeutic antibody is designed to act as an antineoplastic agent, leveraging its dual specificity to modulate immune system responses against cancer cells. Vonsetamig's unique ability to bind to both a tumor necrosis factor receptor superfamily member 17 (TNFRSF17) on malignant cells and the CD3 epsilon (CD3E) on T-cells facilitates a directed immune response towards the tumor environment, making it a critical tool in cancer immunotherapy research.

Atidortoxumab is a human IgG1κ monoclonal antibody specifically designed to target and neutralize Staphylococcus aureus alpha toxin. This antibody plays a crucial role in mitigating the cytotoxic effects induced by the alpha toxin, thereby contributing to the study of bacterial pathogenesis and the development of therapeutic strategies against Staphylococcus aureus infections.

The Anti-FGFR1/CD331 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting FGFR1/CD331. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is crucial for research focusing on the role of FGFR1/CD331 in cellular processes and disease mechanisms, making it an essential tool for both basic research and therapeutic development.

Pateclizumab (MLTA3698A) is a humanized monoclonal antibody specifically targeting lymphotoxin α (LTα), a cytokine transiently expressed on activated B and T cells, including Th1 and Th17 subsets. These cells play a critical role in the pathogenesis of rheumatoid arthritis (RA), making Pateclizumab a valuable tool for research into the mechanisms of this disease and potential therapeutic interventions.

Visugromab (CTL-002) is an IgG4 monoclonal antibody designed to neutralize Growth Differentiation Factor 15 (GDF-15). This antibody has demonstrated synergistic anticancer effects when used in combination with the anti-PD1 antibody Nivolumab. It is particularly effective in treating PD-1/PD-L1 relapsed or refractory metastatic solid tumors, offering a promising therapeutic option for advanced cancer management.

Emactuzumab (RG 7155) is a highly specific monoclonal antibody designed to inhibit the activation of the colony-stimulating factor 1 receptor (CSF1R). It exhibits a high affinity for CSF-1R with a dissociation constant (Ki) of 0.2 nM, effectively blocking CSF-1R dimerization. This antibody is primarily utilized in research focused on various diseases, including diffuse-type tenosynovial giant cell tumor (dt-GCT). Emactuzumab serves as a crucial tool for elucidating the role of CSF1R in disease pathology and for the development of therapeutic strategies targeting this receptor.

BHQ-880 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target Dickkopf-related protein 1 (DKK1). This antibody has a predicted molecular weight of 142.96 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. BHQ-880 is utilized primarily in research focused on understanding and modulating Wnt signaling pathways implicated in various diseases, including cancer and osteoporosis.

Lupartumab (BAY 1112623) is a monoclonal antibody targeting LYPD3 (C4.4A), designed for the development of the antibody-drug conjugate BAY 1129980. This antibody serves as a precise tool in the synthesis of targeted therapies, potentially enhancing the delivery and efficacy of oncologic treatments.

The Anti-SIRPg/CD172g Antibody (KWAR23) is a recombinant human monoclonal antibody specifically targeting Signal-Regulatory Protein Gamma (SIRPG). This antibody binds with high affinity to SIRPG, a protein expressed on the surface of myeloid cells and involved in modulating immune responses. The Anti-SIRPg/CD172g Antibody (KWAR23) is ideal for use in research focusing on immune regulation, signal transduction pathways, and potential therapeutic interventions for diseases involving the immune system.

Zeleciment is a monoclonal antibody of the IgG1κ isotype, specifically targeting the transferrin receptor (TFRC). This antibody binds with high specificity to TFRC, a key membrane protein involved in iron uptake and regulation, making it an essential tool for research into cellular iron metabolism, cancer biology, and related therapeutic areas.

Adalimumab is a recombinant human monoclonal IgG1 antibody that specifically targets and neutralizes tumor necrosis factor alpha (TNF-α). This interaction inhibits the inflammatory response associated with autoimmune diseases, making Adalimumab essential for research in immunology and inflammation.

The Anti-CLEC4C Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CLEC4C. This antibody is composed of a human IgG1 type heavy chain and a human lambda (λ) type light chain. It has a predicted molecular weight of 150 kDa, making it suitable for a variety of biochemical and immunological applications, including flow cytometry, western blotting, and immunohistochemistry. This specificity and configuration ensure high affinity and selectivity towards CLEC4C, a key marker in dendritic cell biology and immune response studies.

The Anti-CD33 Antibody (IMGN-779) is a humanized antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Siglec-3/CD33. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 144.6 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focusing on the biological role and therapeutic targeting of CD33 in various diseases.

Anti-CA19-9 Antibody (1116-NS-19-9) is a chimeric monoclonal antibody of the mouse IgG1, κ subclass, specifically designed to target human CA19-9 antigen. For accurate experimental controls, it is recommended to use Mouse IgG1 kappa Isotype Control in conjunction with this antibody to ensure specificity and consistency in results.

Uliledlimab is a humanized monoclonal antibody that targets CD73, exhibiting potent inhibitory activity. This antibody effectively blocks the enzymatic conversion of extracellular adenosine monophosphate (AMP) to adenosine, a mechanism implicated in tumor evasion of immune surveillance. Uliledlimab is primarily utilized in cancer research, where it serves as a critical tool for studying the role of the adenosine pathway in tumor progression and response to therapy.

Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody designed to bind to programmed death-1 (PD-1) receptor with subnanomolar affinity. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Spartalizumab effectively modulates immune responses. This antibody is primarily utilized in research focused on anaplastic thyroid carcinoma (ATC), providing a valuable tool for investigating immune checkpoint pathways in cancer immunotherapy studies.

The Anti-TMPRSS2 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the TMPRSS2 enzyme. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a molecular weight of approximately 150 kDa. For appropriate isotype controls, researchers should use the Human IgG1 kappa, Isotype Control. This product is ideal for studies focusing on the role of TMPRSS2 in disease processes, particularly in the context of viral entry and pathogenesis.

Pascolizumab (SB-240683) is a humanized monoclonal antibody that targets interleukin-4 (IL-4), a key cytokine involved in inflammatory and allergic responses. This antibody is specifically designed for the investigation of its therapeutic potential in asthma research, offering a promising tool for elucidating the role of IL-4 in asthma pathogenesis and for exploring novel treatment strategies.

Inetetamab is a monoclonal antibody that specifically targets domain IV of the HER2 receptor. This antibody exhibits antitumor activities either as a standalone treatment or in combination with tyrosine kinase inhibitors. Inetetamab's mode of action and its specificity for the HER2 receptor make it a valuable tool in cancer research, particularly in studies focused on HER2-positive tumors.

Lumistobart is a humanized IgG1κ monoclonal antibody that specifically targets signal-regulatory protein alpha (SIRPA). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Brenetafusp is a monoclonal antibody designed to target both CD3E and PRAME. This dual-targeting approach enhances its potential for use in the selective elimination of tumor cells while engaging the immune system via the CD3E component. Brenetafusp holds significant promise for therapeutic applications in oncology, particularly in treatments aimed at PRAME-expressing malignancies.

Morolimumab is a humanized IgG1 monoclonal antibody that specifically targets the RHD antigen, also known as CD240D. This antibody is designed for use in the study of immune-related disorders, providing a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions for these conditions.

Tamrintamab, also known as SC-003 mAb, SC-Mab003, or SC34.28ss1, is an antibody-drug conjugate (ADC) specifically designed to target dipeptidase 3 (DPEP3 or MBD3). DPEP3, a glycosyl phosphatidylinositol-anchored metallopeptidase, is notably overexpressed in ovarian tumors. By binding to cells expressing DPEP3, Tamrintamab mediates targeted cytotoxicity, making it a valuable tool for research into the pathophysiology and potential treatments of ovarian cancer.

The Anti-LY6E Antibody (MLYE4489A), also known as RG-7841, is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the lymphocyte antigen 6 complex, locus E (Ly6E). This antibody is comprised of a human immunoglobulin G2 (huIgG2) heavy chain and a human kappa (huκ) light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, Human IgG2 kappa, Isotype Control is recommended. This product is essential for research focusing on the role of Ly6E in immune response and its potential implications in therapeutic interventions.

Necitumumab is a recombinant human IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR). This antibody is utilized extensively in the study of non-small cell lung cancer (NSCLC), colorectal cancer, and other malignancies characterized by EGFR expression. Its high specificity and affinity for EGFR make it a valuable tool in oncological research, particularly in investigations aimed at elucidating the role of EGFR in tumor pathogenesis and in the development of therapeutic strategies.

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific antibody designed for dual affinity re-targeting (DART) of PD-1 and LAG-3. This therapeutic agent demonstrates high affinity binding to cell-surface expressed PD-1 and LAG-3, with half-maximal effective concentrations (EC50s) of 1.65 nM and 0.41 nM in NS0 cells, respectively. By effectively blocking the interactions between PD-1/PD-L1, PD-1/PD-L2, and LAG-3/HLA (MHC-II), as well as inhibiting PD-1 signaling pathways, Tebotelimab plays a crucial role in restoring the function of exhausted T-cells. This restoration is pivotal in enhancing anti-tumor immunity, making Tebotelimab a significant tool in cancer immunotherapy research.

The Anti-TLR7 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Toll-Like Receptor 7 (TLR7). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for studies focusing on the role of TLR7 in immune response and its implications in autoimmune diseases and therapeutic interventions.